arrow
H

Hongling Peng

Central South University
H指数:28
被引数:2,737

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Orelabrutinib versus chemoimmunotherapy in treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma: a randomized, phase 3 trial

Orelabrutinib与化学免疫疗法在治疗初治慢性淋巴细胞白血病/小淋巴细胞淋巴瘤中的比较: 一项随机,3期试验

2026-07-060
OAAI
Daratumumab-based first-line therapy benefit multiple myeloma patients in a real-world setting: a multi-center retrospective propensity score-match study

达鲁单抗为基础的一线治疗在真实世界环境中对多发性骨髓瘤患者有益:一项多中心回顾性倾向性评分匹配研究

2026-02-050
OAAI
Clinical characteristics and survival outcomes of thymic mucosa-associated lymphoid tissue lymphoma: A multicenter analysis of 82 patients

胸腺黏膜相关淋巴组织淋巴瘤的临床特征与生存结局:一项82例患者的多中心分析

CANCER
IF5.1
2025-12-010
OAAI
Venetoclax combined with homoharringtonine, cytarabine and aclacinomycin as induction therapy in newly diagnosed Chinese acute myeloid leukaemia patients: A multicentre phase II study

维奈克拉联合高三尖杉酯碱、阿糖胞苷和米托蒽醌作为新诊断中国急性髓系白血病患者的诱导治疗:一项多中心II期研究

2025-10-280
PRE